1.65
+0.17(+11.49%)
Currency In USD
| Previous Close | 1.48 |
| Open | 1.51 |
| Day High | 1.68 |
| Day Low | 1.5 |
| 52-Week High | 2.01 |
| 52-Week Low | 0.24 |
| Volume | 1.92M |
| Average Volume | 2.87M |
| Market Cap | 117.33M |
| PE | -3.06 |
| EPS | -0.54 |
| Moving Average 50 Days | 1.3 |
| Moving Average 200 Days | 0.67 |
| Change | 0.17 |
If you invested $1000 in Ovid Therapeutics Inc. (OVID) since IPO date, it would be worth $134.69 as of October 21, 2025 at a share price of $1.65. Whereas If you bought $1000 worth of Ovid Therapeutics Inc. (OVID) shares 5 years ago, it would be worth $315.49 as of October 21, 2025 at a share price of $1.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 03, 2025 11:05 AM GMT
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrantsNEW YORK, Oct. 03, 2025 (GLOBE NEWSWIR
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
GlobeNewswire Inc.
Oct 03, 2025 11:00 AM GMT
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vi
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
GlobeNewswire Inc.
Jul 23, 2025 12:30 PM GMT
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company’s man